Evidence map›Paper›PMID 35863678›Full record

ArticleOsteoarthritis and cartilage2022

Alkylresorcinol, a biomarker for whole grain intake, and its association with osteoarthritis: the MOST study.

J-P Zertuche, G Rabasa, A H Lichtenstein, N R Matthan, M Nevitt, J Torner, C E Lewis, Z Dai, D Misra, D Felson

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in Osteoarthritis and cartilage, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

J-P ZertucheBoston University, USA. Electronic address: plopezze@bu.edu.
G RabasaBoston University, USA. Electronic address: grabasa@bu.edu.
A H LichtensteinTufts University, USA. Electronic address: alice.lichtenstein@tufts.edu.
N R MatthanTufts University, USA. Electronic address: nirupa.matthan@tufts.edu.
M NevittUniversity of California, San Francisco, USA. Electronic address: mnevitt@ucsf.edu.
J TornerUniversity of Iowa, USA. Electronic address: james-torner@uiowa.edu.
C E LewisUniversity of Alabama at Birmingham, USA. Electronic address: celewis@uabmc.edu.
Z DaiFlinders University, College of Medicine and Public Health, Adelaide, Australia. Electronic address: zhaoli.daikeller@flinders.edu.au.
D MisraBeth Israel Deaconess Medical Center, HMS, USA. Electronic address: dmisra@bidmc.harvard.edu.
D FelsonBoston University, USA. Electronic address: dfelson@bu.edu.
Boston University · USTufts University · USBeth Israel Deaconess Medical Center · USUniversity of Alabama at Birmingham Hospital · USUniversity of California, San Francisco · USUniversity of Iowa · US

Funding

Multicenter Osteoarthritis Study (MOST) Second RenewalU01AG019069 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NEVITT, MICHAEL C · 2001 to 2020
$21.7M
Multicenter Osteoarthritis Study (MOST) Second Renewal: Iowa Clinical CenterU01AG018832 · NIA · UNIVERSITY OF IOWA · PI SEGAL, NEIL A, TORNER, JAMES C · 2001 to 2020
$14.1M
Multicenter Osteoarthritis Study (MOST) Second Renewal - Boston UniversityU01AG018820 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FELSON, DAVID TOBIN · 2001 to 2019
$13.6M
Multicenter Osteoarthritis Study (MOST) Second Renewal - UAB Clinical CenterU01AG018947 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LEWIS, CORA E · 2001 to 2020
$13.2M
Research and Evaluation Support Core Unit (RESCU Core)P30AR072571 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Michael Paul Lavalley · 2019 to 2026
$6.9M
Fats, Fiber and OsteoarthritisR01AR071950 · NIAMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FELSON, DAVID TOBIN · 2017 to 2020
$2.2M
NIAMS NIH HHS P30 AR072571NIAMS NIH HHS R01 AR071950NIA NIH HHS U01 AG018820NIA NIH HHS U01 AG018832NIA NIH HHS U01 AG018947NIA NIH HHS U01 AG019069
6 · The paper itself

Abstract

introductionHigher intake of fiber has been associated with lower risk of incident symptomatic osteoarthritis (OA). We examined whether levels of alkylresorcinol (AR), a marker of whole grain intake, were associated with OA in subjects in The Multicenter Osteoarthritis (MOST) Study.

methodKnee x-rays and knee pain were assessed at baseline and through 60-months. Stored baseline fasting plasma samples were analyzed for AR homologues (C17:0, C19:0, C21:0, C23:0, C25:0) and total AR levels (AR sum). Two nested case-control studies, one for incident radiographic OA and one for incident symptomatic OA were performed with participants re-assessed at 15, 30 and 60 months. Multivariable conditional logistic regression with baseline covariates including age, sex, BMI, physical activity, quadriceps strength, race, smoking, depressive symptoms, diabetes and knee injury tested the association of log transformed AR levels with OA outcomes.

resultsSeven hundred seventy-seven subjects were, on average, in their 60's, and most were women. For 60-month cumulative incidence, there was no significant association between quartiles of AR concentration and incident radiographic (e.g., for incident radiographic OA, highest vs lowest quartile of AR sum showed RR = 0.93 (95% CI 0.59, 1.47), and for symptomatic OA RR was 1.22 (95% CI 0.76, 1.94). In secondary analyses examining 30-month incidence, high AR levels were associated with a reduced risk of X-ray OA (RR = 0.31 (95% CI 0.15, 0.64).

conclusionIn primary analyses, AR levels were not associated with risk of OA, but secondary analyses left open the possibility that high AR levels may protect against OA.

Indexed as

OsteoarthritisOsteoarthritis, KneeBiomarkersFemaleHumansKnee JointMaleWhole GrainsBiomarkersAlkylresorcinolBiomarkerDietDietaryfiberOA

Identifiers

PMID35863678
PMCPMC9554937
OpenAlexW4286261462

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.